Xingxing Zang Laboratory


Murali Janakiram  

   Murali Janakiram, MD, MS

Assistant Professor of Medicine
Attending Physician
Division of Hematology Malignancies
Department of Oncology
Montefiore Medical Center/Albert Einstein College of Medicine
Hoffheimer 100, Department of Oncology
Montefiore Medical Center
111, E 210 St

Department of Microbiology & Immunology
Albert Einstein College of Medicine
Forchheimer Building, Room 405
Bronx, NY 10461
Tel: 718-430-4154
Fax: 718-430-8711

Murali Janakiram received his MBBS degree from Madras Medical College in India. He then moved to England where he worked as a Senior House Officer in various subspecialties of Medicine under the University of Liverpool. He did his Internal Medicine residency between 2007 to 2010 at Metro Health Medical Center, Case Western School of Medicine. After his residency, he then joined the Hematology/Oncology fellowship program at the Albert Einstein College of Medicine. He has been in the Zang lab since 08/2012 and was offered Assistant Professor position in 01/2014 in Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine. He received Masters in Clinical Research in 2014. His research interests include investigating the expression and function of coinhibitory B7 molecules [HHLA2 (B7y), B7x, PD-L1, B7H3] in human cancer and clinical trials of cancer immunotherapy.


Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x and B7-H3. Immunological Reviews, 276:26-39, 2017

Cheng H*, Janakiram M*, Borczuk A*, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clinical Cancer Research, 23:825-832, 2017.
(* co-first authors)

Janakiram M, Pareek V, Cheng H, Narasimhulu D, Zang X. Immune checkpoint blockade in human cancer therapy: Lung cancer and hematopoietic malignancy. Immunotherapy, 8:809-819, 2016

Chinai JM*, Janakiram M*, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 36:587-595, 2015
(* co-first authors)

Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families. OncoImmunology, 4: e1026534-1 - e1026534-3, 2015

Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clinical Cancer Research, 21:2359-2366, 2015

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Structure and cancer immunotherapy of the B7 family member B7x. Cell Reports, 9:1089-1098, 2014

Janakiram M, Abadi YM, Sparano JA, Zang X. T cell coinhibition and immunotherapy in human breast cancer. Discovery Medicine, 14:229-236, 2012

Janakiram M, Thirukonda VK, Sullivan M, Petrich AM. Emerging therapeutic targets in diffuse large B-cell lymphoma. Current Treatment Options in Oncology, 13: 82-101, 2012

Ayyappan S, Janakiram M, Raghupathy R. Current and emerging therapies in primary myelofibrosis. Cardiovascular & Hematological Disorders-Drug Targets, 12:6-20, 2012

Antonelli M, Bupathi M, Janakiram M, Hergenroeder P, Khan MA. Acquired erythrocytosis upon treatment with infliximab for ankylosing spondylitis. The Journal of Rheumatology, 38: 581-583, 2011

Saravanan V, Janakiram M, Bankar RN, Kumar S, Nasar A. An unusual cause of paraplegia. British Journal of Hospital Medicine, 67:97, 2006


Xingxing Zang is solely responsible for the content of this site. Comments, concerns and questions regarding it should be addressed to him.

Click here to log in